TY - JOUR T1 - Clinical characteristics of 50404 patients with 2019-nCoV infection JF - medRxiv DO - 10.1101/2020.02.18.20024539 SP - 2020.02.18.20024539 AU - Pengfei Sun AU - Shuyan Qie AU - Zongjan Liu AU - Jizhen Ren AU - Jianing Xi Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/23/2020.02.18.20024539.abstract N2 - Objective To provide reliable evidence of evidence-based medicine for the treatment and prevention of the 2019 novel coronavirus(2019-nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019-nCoV.Methods PubMed,Cochrane Library,Embase and other databases were searched. Some studies on the clinical characteristics of 2019-nCoV infection were collected for Meta-analysisResults 9 studies were included in Meta-analysis, including a total of 50404 patients with 2019-nCoV infection.According to Meta-analysis, among the clinical characteristics of patients with 2019-nCoV infection, the incidence of fever is 90.9%, the incidence of cough is 70.8%, and the incidence of muscle soreness or fatigue is 41%. The incidence of acute respiratory distress syndrome (ARDS) was 14.8%, the incidence of abnormal chest CT was 95.6%, the proportion of severe cases in all infected cases was 21.3%, and the mortality rate of patients with 2019-nCoV infection was 4.8%.Conclusion Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of them have abnormal chest CT examination.Some people have muscle soreness or fatigue, ARDS. Diarrhea, hemoptysis, headache, sore throat, shock and other symptoms only occur in a small number of patients.The mortality rate of patients with 2019-nCoV infection was lower than that of Severe Acute Respiratory Syndrome (SRAS) and Middle East Respiratory Syndrome (MERS).Highlights A total of 9 articles were included in the Meta-analysis, including 50404 patients with 2019-nCoV infection, which was the first Meta-analysis with the largest sample size.The quality of the literature included in this study was high, the analysis was rigorous, and the conclusions drawn by the study were highly credible.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a meta-analysis.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the article.WHOthe World Health Organization2019-nCoVthe 2019 novel coronavirusSRASSevere Acute Respiratory SyndromeARDSAcute Respiratory Distress SyndromeNOSthe Newcastle-Ottawa ScaleMERSMiddle East Respiratory SyndromeACE2Angiotensin Converting Enzyme 2TGF-βTransforming Growth Factor-βChina CDCChinese Center for Disease Control and Prevention ER -